Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
| Autor: | P, Rousselot, S, Labaume, J P, Marolleau, J, Larghero, M H, Noguera, J C, Brouet, J P, Fermand |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Cell Survival
Tumor Suppressor Proteins Plasma Cells Melarsoprol Nuclear Proteins Antineoplastic Agents Apoptosis Oxides Promyelocytic Leukemia Protein Flow Cytometry Lymphocyte Activation Arsenicals Cell Line Neoplasm Proteins Kinetics Arsenic Trioxide Arsenic Poisoning Humans Fluorescent Antibody Technique Indirect Multiple Myeloma Cell Division Transcription Factors |
| Zdroj: | Cancer research. 59(5) |
| ISSN: | 0008-5472 |
| Popis: | Recent data have renewed the interest for arsenic-containing compounds as anticancer agents. In particular, arsenic trioxide (As2O3) has been demonstrated to be an effective drug in the treatment of acute promyelocytic leukemia by inducing programmed cell death in leukemic cells both in vitro and in vivo. This prompted us to study the in vitro effects of As2O3 and of another arsenical derivative, the organic compound melarsoprol, on human myeloma cells and on the plasma cell differentiation of normal B cells. At pharmacological concentrations (10(-8) to 10(-6) mol/L), As2O3 and melarsoprol caused a dose- and time-dependent inhibition of survival and growth in myeloma cell lines that was, in some, similar to that of acute promyelocytic leukemia cells. Both arsenical compounds induced plasma cell apoptosis, as assessed by 4',6-diamidino-2-phenylindole staining, detection of phosphatidylserine at the cell surface using annexin V, and by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. As2O3 and melarsoprol also inhibited viability and growth and induced apoptosis in plasma-cell enriched preparations from the bone marrow or blood of myeloma patients. In nonseparated bone marrow samples, both arsenical compounds triggered death in myeloma cells while sparing most myeloid cells, as demonstrated by double staining with annexin V and CD38 or CD15 antibodies. In primary myeloma cells as in cell lines, interleukin 6 did not prevent arsenic-induced cell death or growth inhibition, and no synergistic effect was observed with IFN-alpha. In contrast to As2O3, melarsoprol only slightly reduced the plasma cell differentiation of normal B cells induced by pokeweed mitogen. Both pokeweed mitogen-induced normal plasma cells and malignant plasma cells showed a normal nuclear distribution of PML protein, which was disrupted by As2O3 but not by melarsoprol, suggesting that the two arsenical derivatives acted by different mechanisms. These results point to the use of arsenical derivatives as investigational drugs in the treatment of multiple myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|